利標品牌(00787.HK)向韓國私募基金出售Spyder品牌業務 涉資4,000萬美元
利標品牌(00787.HK)公布,4月29日附屬Global Brands (Hong Kong) Limited作為賣方,與Alpha Vista訂立單位購買協議,同意出售集團於韓國之若干業務,包括「Spyder」品牌旗下的童裝、男女時裝、鞋履、時裝配飾及相關時尚產品的設計、開發、推廣及銷售,現金代價為4,000萬美元。
該交易交割後,公司餘下業務將包括其所有北美洲及歐洲業務以及其所有品牌管理業務,公司擬動用該交易所得款項以償還部分現有銀行債務。Alpha Vista為韓國一家註冊私募股權投資公司,主要從事私募股權基金管理。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.